| 董文秀,张改连.Ⅰ类组蛋白去乙酰化酶在类风湿关节炎中的研究进展[J].安徽医药,待发表. |
| Ⅰ类组蛋白去乙酰化酶在类风湿关节炎中的研究进展 |
|
| 投稿时间：2024-03-28 录用日期：2024-04-25 |
| DOI： |
| 中文关键词: 类风湿关节炎 组蛋白去乙酰化酶 发病机制 治疗 |
| 英文关键词: |
| 基金项目:山西省留学人员科技活动择优资助项目(20210003) |
|
| 摘要点击次数: 50 |
| 全文下载次数: 0 |
| 中文摘要: |
| 类风湿关节炎(rheumatoid arthritis,RA)是以滑膜炎及血管翳为特征的风湿免疫病,其发病率高、致残性强、预后差,可引起关节损毁,严重影响患者生活质量,给患者带来巨大痛苦。RA的发病与遗传、环境等多种因素相关。组蛋白乙酰化修饰是表观遗传学中的重要机制之一。组蛋白去乙酰化酶(HDACs)对组蛋白乙酰化修饰的调控发挥重要作用。I类HDACs在RA患者中存在表达失调,针对I类HDACs抑制剂能够抑制RA的滑膜增生、炎症以及炎性细胞因子的浸润。以I类HDACs为靶点的药物有望为RA患者提供新的治疗选择。本文就近年来I类HDACs在RA的相关研究进行综述。 |
| 英文摘要: |
| Rheumatoid arthritis (RA) is a rheumatoid immune disease characterized by synovitis and pannus. It has a high incidence, strong disability and poor prognosis, which can cause joint damage, seriously affect the quality of life of patients and bring great pain to patients. The pathogenesis of RA is related to many factors such as heredity and environment. Histone acetylation modification is one of the important mechanisms in epigenetics. Histone deacetylases (HDACs) play an important role in the regulation of histone acetylation modification. Class I HDACs are dysregulated in RA patients, and Class I HDACs inhibitors can inhibit synovial hyperplasia, inflammation and inflammatory cytokine infiltration in RA. Drugs targeting Class I HDACs are expected to provide new treatment options for RA patients. This paper reviews the recent research on Class I HDACs in RA. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
